Stock data
Coherus Oncology, Inc. (CHRS)
Coherus Oncology, Inc. (CHRS) reported net income of US$168.02M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | — | — | -US$181.13M | US$168.02M | — |
| 2024 | — | — | -US$199.65M | US$28.51M | — |
| 2023 | — | — | -US$203.20M | -US$237.89M | — |
| 2022 | — | — | -US$256.88M | -US$291.75M | — |
| 2021 | — | — | -US$263.86M | -US$287.10M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | — | -US$20.63M | — |
| 2026-03-31 | — | -US$38.33M | — |
| 2025-12-31 | — | -US$37.64M | — |
| 2025-09-30 | — | -US$35.53M | — |
| 2025-06-30 | — | US$297.77M | — |
| 2025-03-31 | — | -US$56.57M | — |
| 2024-12-31 | — | -US$50.70M | — |
| 2024-09-30 | — | -US$10.75M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.